Life Sciences Commentary Geoff Nash, Director at Cavendish comments: "We all look forward to a more positive 2024 after two of most challenging years in equity markets ever experienced. Despite this, at Cavendish we continue to deliver for our clients. Since January 2022 we have raised over £105m across 13 secondaries and an IPO in feed additives. This represents over 25% of all activity in the life sciences sector where approximately £400m* was raised in 2022/3. We have lots to execute on in 2024 and look forward to growing our healthcare franchise further.” *excludes fundings sub £2m #lifesciences #healthcare #growthbusiness #capitalmarkets
Cavendish’s Post
More Relevant Posts
-
Anyone interested in Private Equity specifically one in the healthcare industry. On Wednesdays I cover the Healthcare and Pharma industry. This week i looked at a PE firm that raised 1.35 billion. Avesi Partners Closes Second Fund at $1.35 Billion, Introduces Performance-Based Profit Sharing Avesi Partners, a lower midmarket private equity firm focused on healthcare and business services, has successfully closed its second fund, Avesi Partners Fund II LP, at $1.35 billion. This represents a significant increase from their debut fund of $884 million closed in 2021. The new fund, which was oversubscribed and closed at its hard cap, includes a substantial commitment from Avesi itself, demonstrating strong alignment with investors. Managing Partner and CIO Chris Laitala, formerly of H.I.G. Capital and Lindsay Goldberg, highlighted the firm's success in identifying high-growth businesses and partnering with founders to accelerate growth. Read the full story here: https://lnkd.in/dQ3Vk6DN
-
The Sydney Morning Herald shares some of the best long-term investment ideas from leading Australian fund managers, including Dr. David Allen from Plato Investment Management and Jacob Mitchell from Antipodes. David names Novo Nordisk as his stock to watch. The pharmaceuticals & biotechnology giant is a key holding in the Plato Global Alpha Fund. It is now the largest company in Europe, eclipsing LVMH. Jacob calls out Tesco as one of Antipodes' top global stock ideas, noting the market-leading consumer staple maintains circa 30% share of the UK’s in-store grocery market, yet trades at half the multiple of Woolworths Group and Walmart. Learn more about about the Plato Global Alpha Fund: https://lnkd.in/gt-peP9U Learn more about Antipodes' global equities portfolios: https://lnkd.in/dqZMBVFD
-
Value$Canna CFO LLC delivers high-impact financial solutions to cannabis owners and their team members.
Crazy, crazy times in the cannabis industry. Huge, huge potential development & ripple effect from Fed intentions to reschedule from Schedule I to Schedule III. Just what that all means, how it may impact the industry remains to be seen. Including & especially with access to capital/financing. Social equity license holders-their access to capital, their "readiness" to be invested in & financed depends on diligent, thorough preparation & a strong sanity check to their expectations. Here are some "freebies" to help you contemplate the challenges of raising funds in the cannabis space. We can help. #cannabiscapital #cannabisfinancing #cannabisfunding #cannabisinvesting #cannabiscfo #cannabisbanking #cannabislending
-
Founder Alternative Finance Network 🔹 Funding non-traditional businesses since 2009 with debt financing
Learn about #funding options for #cannabisbusiness owners Friday at 3:25. Hall D, Room 210 at the @GreenMarketReport Finance Summit in partnership with @NECANN. #cannabisevents #cannabis #NECANN #GreenMarketReport #cannabisnews
-
-
FD Insights for 19th December 2023. 💰 Blue Planet Environmental Solutions has raised $35 million from The Investment Fund for Developing Countries. 💰 Kapture CX has raised $4 million in a Series A1 round from India Alternatives. 👨💼 GoKwik has appointed Ravi Kant Arora as SVP – Finance. 👨💼 Hemadri Cements has appointed K Suryanarayanan as CFO. 🤝 Sun Pharma has planned to acquire a 16% stake in Lyndra Therapeutics for ₹249 crore. 🤝 BHIVE Group has acquired product engineering firm Praemenio for an undisclosed sum. #businessupdates #fundraising #investing #b2b #corporateupdates #fdinsights #fundoodata #investing #funding #latestbusinessupdates
-
Two great examples of our clients’ continued growth stories on AIM and how recent sell downs have broadened the shareholder base for these firms. #growthbusiness #capitalmarkets #ukeconomy
At Cavendish, we believe AIM is a great platform for owners of businesses as it allows them to source additional capital whilst maintaining an element of control. It also allows the flexibility for the founders to sell down their stakes in a controlled manner. Cavendish has been involved in managing multiple sell downs over recent years and completed two in life sciences in last month, realising £11m in aggregate, both at a discount of less than 5% to the mid price. This is despite ongoing challenges in equity markets. These two sell downs, in Bioventix (£2.4m) and hVIVO (£8.4m) were both oversubscribed and allowed us to introduce a number of high quality investors to the register. Geoff Nash, Corporate Finance Director commented: “We have an ongoing desire to broaden the shareholder base of all our corporate clients and were pleased to be able to do so for both of these fantastic businesses – we brought Bioventix to AIM with a market cap of £28m (now £260m) and started working with hVIVO (then Open Orphan) in mid-2020 when the market capitalisation was £70m (£180m today). If we can help your business, please do get in touch.” #lifesciences #healthcare #growthbusiness #capitalmarkets #AIM
-
The biotech industry is witnessing a significant surge with the advent of GLP-1 medications, revolutionizing the treatment of diabetes and weight loss. JPMorgan’s recent closure of a $500 million biotech venture fund underscores the market’s potential, which is expected to reach $105 billion by 20301. This article delves into the impact of GLP-1 drugs on healthcare and consumer sectors, highlighting the strategic shifts and investment trends shaping the future of the industry.
"The top three choices are obesity, obesity and obesity": JPMorgan's asset-management arm raised over $500 million for a new biotech fund that will invest in weight-loss drugs. The hottest corner of healthcare is a "wide open," according to the fund's chief investment officer, as skyrocketing demand for GLP-1s like Ozempic, Wegovy and Mounjaro is causing shortages. Story by me here. https://lnkd.in/eEYT9KVY
JPMorgan to Wager on Weight-Loss Boom With $500 Million Fund
bloomberg.com
-
Mukka Proteins' Initial Public Offering (IPO) makes a significant impact on the stock market as it debuts on Dalal Street, the financial hub of India. The IPO garners substantial attention from investors and market participants, indicating high interest in the company's public offering. The IPO is likely to have a strong start in trading, with investors eager to capitalize on the opportunity to invest in Mukka Proteins' growth potential. Mukka Proteins' IPO is expected to contribute to the overall activity and sentiment on Dalal Street, potentially influencing broader market trends. Investors closely monitor the IPO's performance, assessing factors such as subscription levels, listing price, and post-listing trading activity to gauge market sentiment and investor appetite for new offerings. The successful debut of Mukka Proteins' IPO reflects confidence in the company's business prospects and highlights investor optimism in the sector. However, investors should exercise caution and conduct thorough due diligence before participating in the IPO, considering factors such as the company's financials, industry dynamics, and market conditions. Watch: https://lnkd.in/gUuJa9sG | Sakshi Batra #ipo #mukkaproteinsipo #ipopriced #dalalstreet #ipopriced
-
🐟 Mukka Proteins dives into the market with SEBI's green light for its IPO! 📈💼 Get ready for a splash in the world of aqua and poultry feed manufacturing. 🌊🐔 Read More👇 https://bit.ly/3sqlw8r #MukkaProteins #IPO #MarketDebut #Investment #SEBI #MPL #BusinessNews #stockmarketnews
-
-
Chief Executive Officer at JobRx | Top 1% Industry SSI rank on LinkedIn | Top 1% Network SSI rank on LinkedIn
Here's Why Vltava Fund Sold Its Stake in CVS Health Corporation (CVS) Vltava Fund, an investment management company, recently released its second-quarter 2024 investor letter. A copy of the letter can be downloaded here. The letter discusses how the firm determines the size of each holding in the portfolio. The firm keeps the number of positions in the portfolio between 20 and 25 considering it as ideal. It gives ample opportunities for diversification. Please review the fund's top five holdings to see its best choices for 2024.
Here's Why Vltava Fund Sold Its Stake in CVS Health Corporation (CVS)
msn.com
